We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

149 hedge funds and large institutions have $303M invested in Karyopharm Therapeutics in 2022 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 39 increasing their positions, 58 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

144% more call options, than puts

Call options by funds: $4.7M | Put options by funds: $1.92M

115% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 13

7% more funds holding

Funds holding: 139 → 149 (+10)

0.12% less ownership

Funds ownership: 5.75% → 5.63% (-0.12%)

33% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 58

39% less capital invested

Capital invested by funds: $499M → $303M (-$197M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
149
Holders Change
+10
Holders Change %
+7.19%
% of All Funds
2.51%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
28
Increased
39
Reduced
58
Closed
13
Calls
$4.7M
Puts
$1.92M
Net Calls
+$2.77M
Net Calls Change
-$5.1M

Top Buyers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
+$10.2M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$5.28M
3
RCMNY
Rubric Capital Management (New York)
New York
+$4.85M
4
ECM
ExodusPoint Capital Management
New York
+$3.83M
5
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$3.52M

Top Sellers

Rank Fund Capital Flow
1
CC
Commodore Capital
New York
-$9.94M
2
ITP
Iron Triangle Partners
Connecticut
-$5.5M
3
Millennium Management
Millennium Management
New York
-$3.96M
4
FCM
Frontier Capital Management
Massachusetts
-$3.95M
5
Bank of America
Bank of America
North Carolina
-$3.89M
Name Holding Trade Value Shares
Change 		Change in
Stake
LOAMS
26
Lombard Odier Asset Management (Switzerland)
Switzerland
$2.32M -$1.6M -17,484 -34%
Bank of America
27
Bank of America
North Carolina
$2.16M -$3.89M -42,454 -57%
Citigroup
28
Citigroup
New York
$2.12M +$2.09M +22,749 +267%
Rafferty Asset Management
29
Rafferty Asset Management
New York
$2.07M -$2.14M -23,302 -43%
Renaissance Technologies
30
Renaissance Technologies
New York
$2.05M +$1.47M +15,980 +111%
Citadel Advisors
31
Citadel Advisors
Florida
$1.84M -$2.73M -29,745 -52%
Voloridge Investment Management
32
Voloridge Investment Management
Florida
$1.75M -$1.76M -19,178 -43%
Macquarie Group
33
Macquarie Group
Australia
$1.72M – – –
UBS Group
34
UBS Group
Switzerland
$1.43M -$1.23M -13,395 -39%
HWAM
35
Hennion & Walsh Asset Management
New Jersey
$1.29M -$606K -6,611 -26%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$1.29M -$64.3K -701 -4%
Susquehanna International Group
37
Susquehanna International Group
Pennsylvania
$1.27M +$4.95K +54 +0.3%
BC
38
Birchview Capital
Vermont
$1.22M – – –
HS
39
HighVista Strategies
Massachusetts
$1.13M +$1.53M +16,692 New
Qube Research & Technologies (QRT)
40
Qube Research & Technologies (QRT)
United Kingdom
$1.1M +$1.49M +16,200 New
UOC
41
UBS O'Connor
Illinois
$1.03M +$1.39M +15,173 New
JAM
42
Jupiter Asset Management
United Kingdom
$1.01M +$1.37M +14,974 New
Jane Street
43
Jane Street
New York
$941K -$1.27M -13,884 -50%
Charles Schwab
44
Charles Schwab
California
$902K +$35.4K +386 +3%
Wellington Management Group
45
Wellington Management Group
Massachusetts
$886K – – –
CSS
46
Cubist Systematic Strategies
Connecticut
$859K +$177K +1,933 +18%
Acadian Asset Management
47
Acadian Asset Management
Massachusetts
$836K -$1.92M -20,908 -63%
JP Morgan Chase
48
JP Morgan Chase
New York
$830K -$3.27M -35,631 -74%
Allianz Asset Management
49
Allianz Asset Management
Germany
$808K +$93.2K +1,016 +9%
Swiss National Bank
50
Swiss National Bank
Switzerland
$725K – – –
1
2
3 4 5

KPTI Hedge Fund Activity: Q2 2022 in Review

149 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q2 2022, worth a combined $303M — down 39% from $499M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new KPTI positions and 13 closed out — a net gain of 15 holders — while 39 added to existing stakes and 58 trimmed.

The largest buyer was Walleye Capital, adding an estimated $10.2M. The largest seller was Commodore Capital, cutting an estimated $9.94M.

  • 149 institutional investors held Karyopharm Therapeutics (KPTI) as of Q2 2022, up from 139 in Q1 2022.
  • Funds reported $303M of Karyopharm Therapeutics stock for Q2 2022, down 39% quarter-over-quarter.
  • 28 funds opened new Karyopharm Therapeutics positions in Q2 2022 and 13 closed out, a net change of +15 holders.
  • The largest Karyopharm Therapeutics buyer in Q2 2022 was Walleye Capital, an estimated $10.2M added.
  • The largest Karyopharm Therapeutics seller in Q2 2022 was Commodore Capital, an estimated $9.94M sold.

Based on aggregated 13F filings for Q2 2022.